HSF2 expression was significantly upregulated in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), HCC, lung squamous cell carcinoma (LUSC) and stomach adenocarcinoma (STAD) and downregulated in breast cancer (BRCA), kidney chromophobe renal cell carcinoma (KICH), kidney renal clear cell carcinoma (KIRC), prostate adenocarcinoma (PRAD), thyroid carcinoma (THCA) and uterine corpus endometrial carcinoma (UCEC) (Figure 1A). This evidence concerns the gene HSF2 and prostate adenocarcinoma.